C12Y 207/04006
Nucleoside-diphosphate kinase
Official title: Nucleoside-diphosphate kinase (2.7.4.6)
C12Y207/04006 (Nucleoside-diphosphate kinase) appears on 9 US grants and 29 published applications in this corpus.
Search patents in C12Y- Granted patents
- 9
- Published applications
- 29
- Assignees
- 13
- Inventors
- 63
- Latest grant
- 30 Jul 2024
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2012 | 0 | 1 |
| 2013 | 0 | 0 |
| 2014 | 0 | 1 |
| 2015 | 0 | 2 |
| 2016 | 0 | 3 |
| 2017 | 0 | 1 |
| 2018 | 2 | 2 |
| 2019 | 0 | 3 |
| 2020 | 2 | 1 |
| 2021 | 2 | 2 |
| 2022 | 0 | 5 |
| 2023 | 2 | 1 |
| 2024 | 1 | 6 |
| 2025 | 0 | 1 |
By publication year.
Recent patents
- Anti-NME antibody and method of treating cancer or cancer metastasis30 Jul 2024US 12,049,514 B2Minerva Biotechnologies Corporation
- Production of steviol glycosides in recombinant hosts21 Nov 2023US 11,821,015 B2Evolva SA
- Recombinant Bacillus subtilis for synthesizing GDP-L-fucose and application thereof14 Feb 2023US 11,578,342 B2Bright Dairy & Food Co., Ltd
- Production of steviol glycosides in recombinant hosts20 Apr 2021US 10,982,249 B2Evolva SA
- Cell-free production of ribonucleic acid23 Mar 2021US 10,954,541 B2GreenLight Biosciences, Inc.
- Cell-free production of carminic acid17 Apr 2025US 2025/0122543 A1Debut Biotechnology, Inc.
- Method for Producing Circular DNA24 Oct 2024US 2024/0352495 A1Moderna Enzymatics Co., Ltd.
- Nme inhibitors and methods of using nme inhibitors22 Aug 2024US 2024/0277803 A1Minerva Biotechnologies Corporation
- Enzymatic synthesis of ntp and nqp27 Jun 2024US 2024/0209406 A1Codexis, Inc.
- Engineered 3-o-kinase variants and methods of use27 Jun 2024US 2024/0209408 A1Codexis, Inc.
Most cited
By later US patents
- Methods and compositions for nucleoside triphosphate and ribonucleic acid production3US 10,858,385 B2GreenLight Biosciences, Inc. · 2020
- Cell-free production of ribonucleic acid3US 10,954,541 B2GreenLight Biosciences, Inc. · 2021
- Anti-NME antibody and method of treating cancer or cancer metastasis3US 12,049,514 B2Minerva Biotechnologies Corporation · 2024
- Production of steviol glycosides in recombinant hosts2US 10,982,249 B2Evolva SA · 2021
- Reduction of lipase activity in product formulations2US 9,932,591 B2University of Delaware · 2018